Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

South Korea Comes to the Fore in Biosimilars Space

618 views

Published on

Aided by government funding and big pharma partnerships, South Korea is staking its claim on biosimilars, with Celltrion and Samsung the main contenders.

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

South Korea Comes to the Fore in Biosimilars Space

  1. 1. South Korea Comes to the Fore in Biosimilars Space Powered by Small World Social www.biolink.us
  2. 2. Powered by Small World Social Aided by government funding and big pharma partnerships, South Korea is staking its claim on biosimilars, with Celltrion and Samsung the main contenders. 2Biolink.us
  3. 3. Powered by Small World Social South Korea is pushing to be a leader in the biopharmaceuticals field, so says a recent Financial Times report. While that country’s Celltrion is already a big player in manufacturing, partnering with Pfizer-owned Hospira, Samsung’s more recent foray into the research and development of biosimilars in particular should be interesting to watch, given the company continues to take a bite out of Apple’s market share in the smartphone/smartwatch space. 3Biolink.us
  4. 4. Powered by Small World Social Samsung has partnered with U.S. pharma company Biogen to form Samsung Bioepis to develop and manufacture biosimilars. It has also secured a marketing agreement with another U.S. group, Merck. 4Biolink.us
  5. 5. Powered by Small World Social According to the Financial Times article, South Korea wants “a big share of the $110 billion of value that Citigroup expects to flow from [originator biologics] companies to biosimilars over the next decade. Seoul has set a goal to increase pharmaceutical exports to Won23tn (USD$20.5 billion) by 2020 – up tenfold from the 2012 figure – when it wants to have three of the world’s top 50 pharma companies”. 5Biolink.us
  6. 6. Powered by Small World Social Celltrion’s Remsima/Inflectra was the first copy of Johnson & Johnson/Merck’s rheumatoid arthritis drug Remicade, the world’s third best- selling drug last year with sales of $10 billion. Launched in Europe in February, this biosimilar is now sold in 40 countries worldwide. And Merck took a hit earlier in the year when Orion Oyj, the company marketing Remsima in Norway, cut the local price for the drug by 69 per cent, nabbing half the market in that country. 6Biolink.us
  7. 7. Powered by Small World Social By partnering with Samsung Bioepis, Merck could make up for this, given Samsung Bioepis is awaiting European regulatory approval for its own Remicade copy, along with their copy of another arthritis drug, Pfizer/Amgen’s Enbrel. And with promising clinical trial data for the two drugs presented at the European League Against Rheumatism (EULAR) Annual Congress in Rome in June, approvals may not be far off. 7Biolink.us
  8. 8. Powered by Small World Social By partnering with Samsung Bioepis, Merck could make up for this, given Samsung Bioepis is awaiting European regulatory approval for its own Remicade copy, along with their copy of another arthritis drug, Pfizer/Amgen’s Enbrel. And with promising clinical trial data for the two drugs presented at the European League Against Rheumatism (EULAR) Annual Congress in Rome in June, approvals may not be far off. 8Biolink.us
  9. 9. Powered by Small World Social An article in FiercePharmaAsia.com quoted Samsung Bioepis as saying it could launch its Enbrel biosimilar in South Korea late this year and in Europe in early 2016. Read More on BioLink: https://biolink.smallworldsocial.com/portal#/?id =557f01b6aae3895e3b5a910f 9Biolink.us
  10. 10. Powered by Small World Social www.biolink.us Visit: https://www.smallworldsocial.com/biolink/ to get the latest in biosimilar news curated from around the world Want to read more about biosimilars?

×